CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs) are considered more effective at reducing breast cancer recurrence than tamoxifen alone in post-menopausal women with hormone receptor-positive breast cancer [29-33], although no impact has been demonstrated on mortality.